Description: Ondine Biomedical Inc. engages in the research, development, and commercialization of antimicrobial photodisinfection therapies. It offers Steriwave, an antimicrobial for nasal decolonization; and SurgENT, a debridement and deep-cleaning catheter designed to reduce biofilm and mucus in the sinuses. The company was founded in 1997 and is based in Vancouver, Canada.
Home Page: www.ondinebio.com
OBI Technical Analysis
1100 Melville Street
Vancouver,
BC
V6E 4A6
Canada
Phone:
NA
Officers
| Name | Title |
|---|---|
| Ms. Carolyn M. Cross C.F.A., CFA, M.B.A., MBA | Founder, CEO & Director |
| Dr. Nicolas G. Loebel Ph.D. | Pres, CTO & Director |
| Mr. Thomas Dawson | Sr. VP of Corp. Devel. |
| Mr. Vipul Shah | VP & CFO |
| Mr. Mike Long | VP of Operations |
| Angelika Vance | VP of Corp. Communications |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.1968 |
| Price-to-Sales TTM: | 56.8321 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |